StreetAlpha.app
Home › Stocks › APRE

Aprea Therapeutics, Inc. (APRE)

$0.23
▼ −53.56%
LAST CLOSE · NOV 20

Aprea Therapeutics develops cancer drugs that target specific genetic mutations in tumors. It last closed at $0.23 on Nov 20, down 53.56% on the day. The next earnings report for APRE is expected around Mon, Mar 15, 2027. For the quarter ended Sep 2026, APRE reported EPS of -$0.09. Over its last 8 reports the stock moved an average of 2.6% the session after earnings. Over the last 12 months APRE insiders bought $61K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is APRE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold APRE.

Key Stats

Last 12 months
Results
Net income
−$14.1M
EPS (diluted)
−$0.57
Valuation
Market cap
$3.2M
14.2M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$37.8M
At Sep 30
Shareholder equity
$34.1M
Shares outstanding
14.2M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$37.1M−$37.1MFY2021FY2022: −$112.7M−$112.7MFY2022FY2023: −$14.3M−$14.3MFY2023FY2024: −$13.0M−$13.0MFY2024FY2025: −$12.6M−$12.6MFY2025

From APRE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · Time not announced
Reported EPS
-$0.09
Quarter ended Sep 2026
Year ago EPS
-$0.47
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.47Dec '24Mar 2025: -$0.66Mar '25Jun 2025: -$0.53Jun '25Sep 2025: -$0.47Sep '25Dec 2025: -$0.28Dec '25Mar 2026: -$0.22Mar '26Jun 2026: -$0.07Jun '26Sep 2026: -$0.09Sep '26Latest -$0.09
Revenue by quarter
Not enough quarters on file yet.
How APRE moved after its last 8 reports
Average move the session after a report ±2.6%
Nov 4, 2026Time not announced−1.9%
Aug 12, 2026Time not announced+3.5%
May 13, 2026Time not announced−2.2%
Mar 16, 2026Time not announced+2.7%
Nov 12, 2025Time not announced−4.5%
Aug 12, 2025Time not announced+0.6%
May 14, 2025Time not announced+2.0%
Mar 25, 2025Time not announced−3.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on APREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on APRE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on APRE

Technical Analysis

APRE · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 103% below its 20 day and 156% below its 50 day average. It is 218% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 25), oversold. The nearest support is the 52 week low at $0.20, and the nearest resistance the Pivot at $0.31.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 30.9%/day
Key levels
$1.4952 week high+547.8%
$0.73200 day average+217.4%
$0.65100 day average+182.6%
$0.5950 day average+156.5%
$0.53Swing high (Nov 9)+130.4%
$0.4620 day average+100.0%
$0.42Pivot R1+82.6%
$0.31Pivot+34.8%
$0.23Last close
$0.2052 week low−13.0%
$0.12Pivot S1−47.8%
Indicators
RSI (14)25.47Oversold below 30Oversold
MACD-0.06Below its signal lineBearish
Stochastic43.9Middle of its rangeNeutral
ADX (14)32.4Trending down
Williams %R-92.3Oversold below −80, overbought above −20Oversold
CCI (20)-305.8Oversold below −100, overbought above 100Oversold
Rate of change−55.8%Change over 10 sessionsBearish
ATR (14)$0.07Typical daily range, 30.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for APRE

What happened before

See how APRE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow APRE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How APRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for APREHow many large options trades hit APRE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

APRE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲13 buying vs 11 selling
  • ▲Held by funds +5.5 pts
  • ▲Funds holding +1
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2928+3.6%
In funds' top 1000–
Held by funds23.6%18.2%+5.5 pts
New / increased6 / 78 / 6−7.1%
Reduced / sold out5 / 65 / 2+57.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See APRE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

APRE Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$61K4 buys · 3 insiders
Sold$00 sales · 0 insiders
2025-12 bought $31K2026-01 bought $30KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jan 30John P. HamillSrVP/CFO/Prin Fin & Acct OfcrBuy5,700$0.89$5K
Jan 30Oren GiladPresident/CEOBuy28,100$0.89$25K
Dec 10, 2025John P. HamillSrVP/CFO/Prin Fin & Acct OfcrBuy5,000$1.17$6K
Dec 10, 2025Marc DueyDirectorBuy21,459$1.17$25K
Apr 3, 2025Oren GiladPresident/CEOBuy5,500$1.84$10K
Every insider buy and sale for APRE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See APRE insider trades →

From SEC Form 4 filings by APRE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether APRE is in one of them and how their past APRE trades turned out.

APRE in the AI portfolios
Loading…

APRE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered APRE in an article yet. Here's the latest on the wider market.

APRE in the news

About Aprea Therapeutics

Aprea Therapeutics is a pharmaceutical company based in Doylestown, Pennsylvania, that develops cancer drugs. It focuses on treatments designed to target specific genetic mutations found in certain tumors. Its lead candidates are small molecule drugs, APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor, which are in clinical trials. The company aims these treatments at patients whose cancers carry particular mutations, and its drugs are still in development.

Headquarters
Doylestown, PA